Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;93(2):429-35; discussion 436-7.
doi: 10.1016/j.athoracsur.2011.10.061.

Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging

Jennifer Q Zhang  1 , Craig M Hooker, Malcolm V Brock, James Shin, Sue Lee, Remealle How, Noreli Franco, Helen Prevas, Alicia Hulbert, Stephen C Yang
Affiliations
Review

Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging

Jennifer Q Zhang et al. Ann Thorac Surg. 2012 Feb.

Abstract

Background: It remains unclear if patients with clinical stage T2 N0 (cT2 N0) esophageal cancer should be offered induction therapy vs surgical intervention alone.

Methods: This was a retrospective cohort study of cT2 N0 patients undergoing induction therapy, followed by surgical resection, or resection alone, at the Johns Hopkins Hospital from 1989 to 2009. Kaplan-Meier analysis was used to compare all-cause mortality in cT2 N0 patients who had resection alone vs those who had induction chemoradiation therapy, followed by resection.

Results: A study cohort of 69 patients was identified and divided into two groups: 55 patients (79.7%) received induction therapy and 14 (20.3%) did not. No statistically significant difference in 5-year survival rate was observed for the two groups: 49.5% for the resection-only group and 53.8% for the induction group. More than 50% of cT2 N0 patients were understaged.

Conclusions: For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear. Induction therapy for cT2 N0 did not translate into a statistically significant improvement in survival. However, due to the significant understaging of T2 N0 patients, we recommend neoadjuvant therapy to all cT2N0 patients before operation.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Kaplan-Meier curves of overall survival rates for 14 esophageal cancer patients staged as cT2 N0 who underwent operations alone vs 55 cT2 N0 patients who received neoadjuvant chemoradiation therapy, followed by operation, with 5-year survival rates of 49.5% vs 53.8%, respectively.
Fig 2
Fig 2
Kaplan-Meier curves of recurrence-free survival rates for 10 esophageal cancer patients staged as cT2 N0 who underwent operations alone vs 50 cT2 N0 patients who received neoadjuvant chemoradiation therapy, followed by an operation, with 5-year recurrence-free survival rates of 80% vs 63%, respectively. This analysis excluded 7 patients who were margin-positive and 2 patients with unknown margin status.
See this image and copyright information in PMC

Comment in

References

    1. Rohatgi A, Naji S, Hamouda A, et al. Effect of understaging of early oesophageal cancers on treatment. J Clin Oncol. 2009;(27(suppl)) abstr el5572.
    1. Mariette C, Seitz F, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase HI trial FFCD 9901. J Clin Oncol. 2010;28(15 suppl) abstr 4005. - PubMed
    1. Hurmuzlu M, Øvrebø K, Monge OR, Smaaland R, Wentzel-Larsen T, Viste A. High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. World J Surg Oncol. 2010;8:46. - PMC - PubMed
    1. Stiles B, Mirza F, Coppolino A, et al. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg. 2011;92:491–498. - PubMed
    1. Rice T, Mason D, Murthy S, et al. T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg. 2007;133:317–324. - PubMed

MeSH terms